A summary of the safety data from the phase 3 trials of upadacitinib in psoriatic arthritis

Author: Claire Barnard

With upadacitinib now approved for psoriatic arthritis (PsA) in Europe and under consideration by the US FDA, we round up the key safety data on the Janus kinase (JAK)-1 selective inhibitor from the phase 3 studies, SELECT-PsA 1 and SELECT-PsA 2.

A summary of the efficacy data from these studies and other JAK inhibitors in patients with spondyloarthropathies can be found here.